From July 1, 2021 to September 30, 2021, the company has repurchased 2,886,900 shares, representing 0.52% for CNY 29.81 million. With this, the company has completed the repurchase of 19,086,325 shares, representing 3.39% for CNY 184.47 million under the buyback announced on February 2, 2021.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
24.21 CNY | -0.66% | -2.34% | +41.50% |
May. 13 | Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug | MT |
Apr. 25 | Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+41.50% | 1.89B | |
+37.29% | 6.02B | |
-21.28% | 4.19B | |
+4.52% | 3.25B | |
-18.16% | 2.87B | |
-7.70% | 2.37B | |
-4.05% | 1.58B | |
-15.56% | 1.54B | |
-14.62% | 1.5B | |
+40.06% | 1.45B |
- Stock Market
- Equities
- 600285 Stock
- News Henan Lingrui Pharmaceutical Co., Ltd.
- Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.